Clinical Prioritization of Adverse Events Associated With Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Patients: Insights From the FDA Adverse Event Reporting (FAERS) System
Restricted accessLetterFirst published online 2026
Clinical Prioritization of Adverse Events Associated With Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Patients: Insights From the FDA Adverse Event Reporting (FAERS) System
LiuYLiGWangCChenJChenL.Comparative safety analysis of Hedgehog inhibitor preparations: insights from the FAERS database. Expert Opin Drug Saf. 2025;2025:1-8. doi:10.1080/14740338.2025.2466668
2.
van WindenMECBronkhorstEMVischMB, et al. Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: results from the prospective, multicenter BATOA cohort. J Am Acad Dermatol. 2022;86(5):1010-1019. doi:10.1016/j.jaad.2021.05.041
3.
CeccoSPulighedduSFusaroliM, et al. Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System. Target Oncol. 2024;19(3):435-445. doi:10.1007/s11523-024-01058-9
4.
MockaSFerraroSArdiniM, et al. Sonidegib induced rhabdomyolysis in kidney transplant patient: a case report. J Parathyr Dis. 2023;11(1):e11204. doi:10.34172/jpd.2023.11204
5.
MorzeJDanielewiczAHoffmannGSchwingshacklL.Diet quality as assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension score, and health outcomes: a second update of a systematic review and meta-analysis of cohort studies. J Acad Nutr Diet. 2020;120(12):1998-2031.e15. doi:10.1016/j.jand.2020.08.076
